AR033830A1 - Uso de los antagonistas de los receptores de la il-8 en el tratamiento de las infecciones viricas - Google Patents

Uso de los antagonistas de los receptores de la il-8 en el tratamiento de las infecciones viricas

Info

Publication number
AR033830A1
AR033830A1 ARP010103395A ARP010103395A AR033830A1 AR 033830 A1 AR033830 A1 AR 033830A1 AR P010103395 A ARP010103395 A AR P010103395A AR P010103395 A ARP010103395 A AR P010103395A AR 033830 A1 AR033830 A1 AR 033830A1
Authority
AR
Argentina
Prior art keywords
antagonist
manufacture
viric
antagonists
infections
Prior art date
Application number
ARP010103395A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR033830A1 publication Critical patent/AR033830A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Uso de una cantidad efectiva de un antagonista de los receptores de la IL-8 para la manufactura de un medicamento para tratar la sintomatología del resfriado común causado por infección de rinovirus humano, otros enterovirus, herpesvirus, coronavirus, influenzavirus, parainfluenzavirus, virus respiratorio sincitial o adenovirus en un humano que lo necesite. Uso del antagonista mencionado en conjunción con un antihistamínico, un anti inflamatorio. Uso del antagonista en done se administra oralmente o por inhalación. Uso del antagonista para la manufactura de un medicamento para tratar el asma, bronquitis crónica, enfermedad pulmonar obstructiva crónica, otitis media, sinucitis y neumonía.
ARP010103395A 2000-07-18 2001-07-16 Uso de los antagonistas de los receptores de la il-8 en el tratamiento de las infecciones viricas AR033830A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21905300P 2000-07-18 2000-07-18

Publications (1)

Publication Number Publication Date
AR033830A1 true AR033830A1 (es) 2004-01-07

Family

ID=22817645

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103395A AR033830A1 (es) 2000-07-18 2001-07-16 Uso de los antagonistas de los receptores de la il-8 en el tratamiento de las infecciones viricas

Country Status (17)

Country Link
EP (1) EP1307190A4 (es)
JP (1) JP2004509852A (es)
KR (1) KR20030019587A (es)
CN (1) CN1449285A (es)
AR (1) AR033830A1 (es)
AU (1) AU2001273497A1 (es)
BR (1) BR0112603A (es)
CA (1) CA2418162A1 (es)
CZ (1) CZ2003132A3 (es)
HU (1) HUP0300754A3 (es)
IL (1) IL153921A0 (es)
MX (1) MXPA03000500A (es)
NO (1) NO20030201L (es)
NZ (1) NZ523659A (es)
PL (1) PL365886A1 (es)
WO (1) WO2002005814A1 (es)
ZA (1) ZA200300474B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008509143A (ja) * 2004-08-04 2008-03-27 シェーリング コーポレイション 気道疾患の処置のためのプレコナリルを含む薬学的処方物
PE20170185A1 (es) * 2014-05-12 2017-04-01 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones farmaceuticas para tratar enfermedades infecciosas
BR112022018294A2 (pt) * 2020-03-26 2023-01-10 Dompe Farm Spa Inibidores de cxcl8 para uso no tratamento de covid-19
EP3884932A1 (en) * 2020-03-26 2021-09-29 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitors for use in the treatment of covid-19
EP4008325A1 (en) * 2020-12-02 2022-06-08 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitors for use in the treatment of covid-19

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547979A (en) * 1992-03-30 1996-08-20 Smithkline Beecham TNF inhibition
WO1996005836A2 (en) * 1994-08-25 1996-02-29 Medical University Of South Carolina Methods of treating cold symptoms using pentoxifylline
JPH11503110A (ja) * 1995-02-17 1999-03-23 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体拮抗剤
SE9802729D0 (sv) * 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
SE9802937D0 (sv) * 1998-09-01 1998-09-01 Astra Pharma Prod Novel compounds

Also Published As

Publication number Publication date
KR20030019587A (ko) 2003-03-06
CZ2003132A3 (cs) 2003-09-17
ZA200300474B (en) 2004-08-17
WO2002005814A1 (en) 2002-01-24
AU2001273497A1 (en) 2002-01-30
BR0112603A (pt) 2004-08-24
HUP0300754A3 (en) 2009-03-02
PL365886A1 (en) 2005-01-10
NZ523659A (en) 2006-01-27
MXPA03000500A (es) 2003-06-24
JP2004509852A (ja) 2004-04-02
NO20030201D0 (no) 2003-01-15
EP1307190A1 (en) 2003-05-07
IL153921A0 (en) 2003-07-31
HUP0300754A2 (hu) 2003-08-28
NO20030201L (no) 2003-03-17
CN1449285A (zh) 2003-10-15
EP1307190A4 (en) 2007-08-22
CA2418162A1 (en) 2002-01-24

Similar Documents

Publication Publication Date Title
Ding et al. The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function
JP2023528810A (ja) レムデシビル治療方法
CR8918A (es) Derivados de triazolopiridinilsulfanilo como inhibidores de quinasa map p38
DK1326595T3 (da) Administration af resveratrol til at behandle inflammatoriske respiratoriske lidelser
BR0015908A (pt) Emprego de compostos org nicos no tratamento de doenças
NO20075287L (no) Kombinasjon av antikolinergika og leukotnen-reseptorantagonister for behandling av andedrettslidelser
Brennecke et al. Is inhaled furosemide a potential therapeutic for COVID-19?
CO5200855A1 (es) Uso de csaids en infecciones por rinovirus
BR0313718A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, métodos para tratar um indivìduo humano ou animal sofrendo de uma condição que é mediada por cox-2 e para tratar um indivìduo humano ou animal sofrendo de um distúrbio inflamatório, e, uso de um composto
Du et al. Lianhuaqingwen capsule inhibits influenza-induced bacterial adhesion to respiratory epithelial cells through down-regulation of cell adhesion molecules
AR033830A1 (es) Uso de los antagonistas de los receptores de la il-8 en el tratamiento de las infecciones viricas
Bonville et al. Ribavirin and cysteinyl leukotriene-1 receptor blockade as treatment for severe bronchiolitis
Majdalawieh et al. Immunomodulatory and anti-inflammatory effects of berberine in lung tissue and its potential application in prophylaxis and treatment of COVID-19
EA200800071A1 (ru) Производные бензофуранила как ингибиторы 5-нт6-рецептора
CN101518592A (zh) 一种用于小儿外感风热的颗粒及其制备方法
Liu et al. Pharmacological inhibition of poly (ADP-ribose) polymerase by olaparib ameliorates influenza-virus-induced pneumonia in mice
AR030753A1 (es) Uso de moduladores-proteina de il-8, groalfa, grobeta, grogamma, nap-2, y ena-78, para tratar infecciones viricas
CN106309558A (zh) 一种鼻腔喷雾剂
CA3174328A1 (en) Furosemide compositions and uses thereof for supportive therapy in coronavirus infection
Dennie Safety and Efficacy of 0.5% Carbomer 980 Gel for Treatment of Symptoms of Common Cold: Results of 2 Randomized Trials
Garg et al. Tobacco: An invisible and immediate threat for COVID 19
EA200400639A1 (ru) Фармацевтическая комбинация агонистов аденозиновых a-2a и бета-2-адренергических рецепторов
UY27564A1 (es) Combinación farmacéutica.
UY27565A1 (es) Combinación farmacéutica.
Rose Miscellaneous therapy for COVID-19. A systematic review

Legal Events

Date Code Title Description
FA Abandonment or withdrawal